None

Aadi Bioscience announces the U.S. launch of its first patented product, sirolimus albumin-bound nanoparticle injection (FYARRO), for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell neoplasm (PEComa) It is included in the NCCN guidelines as the only mTOR inhibitor of choice for the treatment of malignant PEComa. It is the first treatment for this extremely rare sarcoma and is marketed under the trade name FYARRO.

The World Health Organization (WHO) defines advanced malignant perivascular epithelioid cell tumors as mesenchymal tumors composed of unique cells that display localized connections with the vessel wall. It has been shown that malignant perivascular epithelioid cell tumors often contain alterations in the TSC1 or TSC2 genes, leading to activation of the mTOR pathway, making mTOR a reasonable therapeutic target for this disease. Sirolimus in sirolimus albumin-bound nanoparticle injection is an mTOR inhibitor. The most common adverse reactions reported by more than 30% of patients were stomatitis, fatigue, rash, infection, nausea, edema, diarrhea, musculoskeletal pain, weight loss, decreased appetite, cough, vomiting, and dysgeusia.

The original drug of sirolimus albumin-bound nanoparticle injection has not yet been marketed in China, so it is not included in medical insurance. The US version of sirolimus albumin-bound nanoparticle injection Original drug, specifications The price of each 100mg tube may be around RMB 60,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Sirolimus Albumin-Bound Nanoparticle Injection on the market. For more drug information and specific prices, please consult Yaode Medical Consultants.